Latest Conference Coverage

The global head of medical affairs-neurology at Janssen Pharmaceutical discussed 2 studies presented at the ACTRIMS Forum 2021 involving fatigue among patients with multiple sclerosis.

Researchers retrospectively analyzed patient follow-ups and found that 50% of patients were ultimately diagnosed with multiple sclerosis.

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical provided his expectations for the upcoming ACTRIMS Forum.

The director of the Dartmouth Epilepsy Program and chairwoman of AES 2020 discussed some of the major topics from the previously completed annual meeting and where epilepsy research is trending.

Despite significant improvements in Dravet syndrome, non-statistically significant reductions were observed in children with Lennox-Gastaut Syndrome.

The director of the Dartmouth Epilepsy Program provided an overview of some of the critical unmet needs within ongoing epilepsy research following the recent AES Annual Meeting.

Data suggest that treatment-emergent adverse events with adjunctive brivaracetam increased in incidence by number of lifetime AEDs.

The neurologist from Cleveland Clinic discussed perampanel’s unique mechanism of action.

The director of the Dartmouth Epilepsy Program discussed a few of the notable highlights and themes from the recently completed American Epilepsy Society Annual Meeting.

Valproic acid’s efficacy as a monotherapy is complicated by its previously demonstrated unsuitability for pregnant women.

Specific health-related quality of life measures in physical activities, well-being, cognition, and social activities were improved among those who underwent the laser ablation procedure.

The director of the Mid-Atlantic Epilepsy and Sleep Center discussed his team’s investigations into predicting responders and adverse events.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed the different medications that cenobamate was used with.

William Rosenfeld, MD, discusses the decreases his team observed in concomitant medication use with cenobamate in patients with focal seizures.

The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to catch refractory epilepsy early and look for the most efficacious treatments for their patients.

Although the percentage of total seizures arising from REM was low, it is notable that 2 out of 26 patients (7.7%) had REM-onset seizures.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team saw a roughly 25% decrease in the mean use of concomitant ASMs.

The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to try and find the right medications for their patients as early as possible.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team succeeded at titrating cenobamate early in the study.

The director of the Mid-Atlantic Epilepsy and Sleep Center urged physicians to actively look for new medications for patients to try.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team studied the interactions of ASMs and cenobamate.

The director of the Mid-Atlantic Epilepsy and Sleep Center also noted how serious adverse effects from treatment can be detrimental to patients’ lives.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how his team worked to reduce deleterious ASM interactions.

The director of the Mid-Atlantic Epilepsy and Sleep Center also urged physicians to not give up on the search for effective AEDs for their patients.

The pediatric neurologist and epilepsy specialist at Colorado Children’s Hospital discussed how the treatment landscape for patients with Lennox-Gastaut syndrome could alter if fenfluramine is approved.

The neurologist from the Comprehensive Epilepsy Care Center for Children and Adults, in St. Louis, Missouri, discussed how patients with intractable epilepsy found cenobamate effective.

The neurologist from Universitätsmedizin Berlin and Berlin Institute of Health provided his insight on the reasons for the limited number of FDA-approved seizure forecasting devices.

Efficacy was observed in patients with DEEs such as West Syndrome, Lennox-Gastaut syndrome, and Dravet syndrome.